RxDoctor Payments DataLook up a doctor →

Ameer Khowaja, MD

Endocrinology, Diabetes & Metabolism · Minneapolis, MNNPI 1366672701

Payments from drug & device makers

$27,992in general payments, 2019–2025

Across 1,017 payments — averaging $27.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Insulet Corporation$10K
  • Novo Nordisk$3K
  • Tandem Diabetes Care, Inc.$2K
  • Dexcom, Inc.$1K
  • Amgen$982
  • Lilly USA, LLC$960
  • plus $10K from 52 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Insulet Corporation78$9,582
Novo Nordisk243$3,414
Tandem Diabetes Care, Inc.14$1,643
Dexcom, Inc.43$1,479
Amgen(2 entities)54$982
Lilly USA, LLC57$960
Abbott42$843
AstraZeneca37$801
Mannkind Corporation34$722
Boehringer Ingelheim29$617
AbbVie35$566
Medtronic(2 entities)34$562
Antares Pharma, Inc.58$530
Corcept Therapeutics24$470
Sanofi-aventis U.S. LLC22$415
Xeris Pharmaceuticals, Inc.21$391
Recordati_rare_diseases_inc.11$361
Radius Health, Inc.17$356
Amarin Pharma, Inc.16$309
Johnson & Johnson14$255
Zealand Pharma US, Inc.11$236
EUSA Pharma (US) LLC4$228
Amneal Pharmaceuticals LLC8$178
BETA Bionics, Inc.7$168
Merck17$155
Cequr Corporation4$141
IBSA Pharma Inc.9$131
Paratek Pharmaceuticals, Inc.1$125
Ultragenyx Pharmaceutical Inc.5$95
Neurocrine Biosciences, Inc.4$94
Sequel Med Tech, LLC5$94
Kyowa Kirin, Inc.4$86
Averitas Pharma Inc.4$85
Bayer4$81
Ascendis Pharma Endocrinology Inc3$80
Ipsen Biopharmaceuticals, Inc4$74
Novartis4$68
Esperion Therapeutics, Inc.4$64
Acerus Pharmaceuticals Corporation3$53
Currax Pharmaceuticals LLC3$44
Pfizer3$40
Chiesi USA, Inc.2$38
Intuity Medical Inc2$37
Boston Scientific1$37
Madrigal Pharmaceuticals2$35
Nalpropion Pharmaceuticals LLC2$32
GRT US Holding, Inc.2$27
Nevro Corp.1$27
Althera Pharmaceuticals LLC2$25
Ascensia Diabetes Care US Inc.1$21
BD1$21
Enterra Medical, Inc.1$20
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC1$20
Amryt Pharma Holdings Ltd1$19
Lifescan, Inc.1$17
Valeritas, Inc.1$13
Shire North American Group Inc1$13
OPKO Pharmaceuticals, LLC1$13

How this compares

$27,992 in reported general payments places this provider in the 75th percentile of 120 endocrinology, diabetes & metabolism providers in Minnesota.

See all endocrinology, diabetes & metabolism providers in Minnesota →

Medicare billing

Part B allowed, 2024
$257,287
Medicare patients
299
Services billed
3,857

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Minneapolis

See the full list for Minnesota →

Where these figures come from

Is this you, or does something look wrong? →